

ASX/ Media Release 8 March 2018

OncoSil Company Update Presentation

Sydney, Australia, 8 March 2018: OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to release a new company investor presentation. The presentation outlines OncoSil's compelling investment case and strategy following the release of new positive clinical data and will be used to support ongoing investor and commercial licensing discussions.

Key highlights:

- Clear mission to commercialise a **breakthrough implantation radiation treatment** for Pancreatic cancer
- Targeting a >\$2bn market opportunity to improve standard of care
- Current and previous clinical studies show excellent local disease control and safety
- Manufacturing and logistics optimised for commercialisation
- US FDA-approved IDE in place, safety run-in underway
- Submission of 16 week 20 patient data to EU Notified Body by 31 May 2018

Company	Media
Mr Daniel Kenny	Ben Walsh
CEO & Managing Director	WE Buchan
E: daniel.kenny@oncosil.com.au	E: <u>bwalsh@buchanwe.com.au</u>
T: +61 2 9223 3344	M: 0411 520 012

- ENDS -

About OncoSil

OncoSil[™] is a clinical-stage medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil[™] is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil[™] is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil[™] in the European Union (EU) is under review with commercial launch planned subject to approval.

The U.S Food and Drug Administration granted an Investigational Device Exemption (IDE) in July 2016 with approval to conduct a clinical study of the OncoSil[™] device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$2b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.



Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forwardlooking statements contained in this document as a result of new information, future events or developments or otherwise.



Company Update March 2018

Advancing Pancreatic Cancer Treatment

OncoSil Medical

OncoSil Medical | Investment Highlights

1	Clear mission	Commercialising a breakthrough implantation radiation treatment for Pancreatic cancer	
2	Sound science	 Current and previous clinical studies demonstrate: Excellent Local Disease Control Significant reduction in tumour size and volume Excellent safety and tolerability profile Ease of implantation 	
3	Clear strategic path	 Targeting >\$2bn market opportunity to improve standard of care US FDA-approved IDE in place, safety run-in underway EU regulatory approval, CE Marking expected near-term Highly experienced management team; strong clinical and commercial pedigree Manufacturing and logistics optimised for supply of commercial quantities At a potential value inflection point with multiple paths to commercialisation 	

OncoSil Medical

OncoSil[™] is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer


First in class technology

- Proprietary brachytherapy (internal radiation) medical device
- Cancer is treated by implantation of radioactive microparticles into a tumour via ultrasound guided endoscopy with negligible surrounding healthy tissues damage
- Patent protected in all major geographies
- Class III Medical device in the US and AIMD in EU

Financial information

Share price (as at 6-Mar-18)	A\$0.14
52 week range	A\$0.08-0.18
Shares on Issue	484.9m
Market capitalisation	A\$67.9m
Cash (31 December 2017)	A\$5.2m
Debt (31 December 2017)	Nil
Enterprise value	A\$62.7m

Share price performance (1 year)



Substantial shareholders

Regal Funds Management	7.5%
Webinvest	5.1%
Management and Directors	14.1%

About the OncoSil[™] device

An implantable radiotherapy medical device targeting pancreatic cancer



- OncoSilTM is a **single-use brachytherapy device**
- \oplus
- Delivered through **microparticles**: 30-micron silicon particles contain beta-emitting Phosphorus-32 (³²P)
 - OncoSilTM Microparticles are inserted **directly into the tumour**
- \bigoplus
- Radiation from the microparticles causes direct damage to cancer cell DNA. The device being active for approximately 3 months after implantation



Microparticles stay in the tumour permanently



Implantation procedure

Studies continue to show the device implantation is technically straightforward




OncoSil[™] dose is suspended in a specially formulated fluid for implantation



Endoscope guided into the upper intestine

Using CT or real-time imaging, the needle is guided into the target lesion (tumour)



OncoSil[™] injected directly into the tumour


OncoSil at a potential value inflection point

The Company is well positioned to realise value of OncoSil[™] device

	Current focus	
Before 2015: Demonstrate potential	2016 to 2018: Satisfy regulatory obligations	2018 onwards: Path to commercialisation
 4 studies show potential of OncoSil™ to treat pancreatic & primary liver (HCC) cancer 	 Secured US FDA IDE approval Initiated PanCO & OncoPac-1 clinical studies Highly positive early safety, efficacy and implant delivery data consistent with results from previously completed studies 	 Secure strategic partnerships and licensing agreements in all key geographies Secure licensing agreements in unique geographies Leverage potential for broader distribution, capital and market support and exposure

Clinical pathway overview

PanCO and OncoPaC-1 to inform future studies



PanCO study – positive results to date

Positive clinical data on 20 patients (at Week 8) and 14 patients (at Week 16)

Patients recruited and implanted

- **38 patients** enrolled in the study¹
- 28 patients implanted¹

Clinical performance	 Excellent local Disease Control Rate (DCR) of 100% (Week 8) and 87% (Week 16) 4 out of 20 implanted patients have achieved a Partial Response (Partial Response defined as a reduction in tumour longest diameter of at least 30% from baseline) 3 out of 20 implanted patients now considered for surgical resection (Resection is the only potential cure for pancreatic cancer, demonstrating possibility of improved outcomes in patient group deemed inoperable at time of study entry) Substantial tumour volumetric reduction observed in patients Up to 73% volumetric reduction at Week 8 (median volumetric reduction 29%) Up to 72% volumetric reduction at Week 16 (median volumetric reduction 39.5%)
Safety	 No Serious Adverse Events (SAEs) attributed to device or implantation procedure (SAEs related to chemotherapy or cancer progression) No evidence of radiation toxicities No other safety concerns identified to date
Implantation procedure	OncoSil [™] device delivery via EUS considered straightforward for implantation

Significant opportunity for OncoSil

Current available treatment for pancreatic cancer

- Surgery (resection), if diagnosed early enough
- Chemotherapy (Gemcitabine and Abraxane)



External radiation therapy

Issues with current standard of care

- Symptoms often unnoticed until cancer has metastasised; poor prognosis even with therapy:
 - Median survival ~8 months¹
 - 5 year survival less than 5%¹
- Surgery not feasible in 85% of patients
- Chemotherapeutic treatments limited effectiveness and are very toxic
- Radiation therapy is toxic to the patient's GI tract

The opportunity for OncoSil

- Only two drugs to have made significant improvements in pancreatic cancer in over 20 years:
 - Gemcitabine approved over 21 years ago and Abraxane approved in 2013
 - Median overall survival has increased by only 2 months (to 8.5 months) over the past 20 years

Significant opportunity for OncoSil to become standard of care in combination with Chemotherapy

1. American Cancer Society 2010 Accessed on 9 September 2015

Positive reception at key conferences

Early study data presented at European Association of Nuclear Medicine (EANM) Annual Congress and European Society of Medical Oncology (ESMO)



The EANM is the **largest organisation** dedicated to Nuclear Medicine in Europe



OncoSil presented early study results to EANM Annual Congress in Vienna on 21 October 2017



ESMO is Europe's **leading non-profit medical oncology organisation**



OncoSil presented details of its trial design to ESMO World Congress on Gastrointestinal Cancer in Barcelona in July 2017

Future conference presentations in 2018



12TH WORLD CONGRESS OF THE WORLD FEDERATION OF NUCLEAR MEDICINE AND BIOLOGY 20-24 April 2018 | MELBOURNE, AUSTRALIA

World Congress of the World Federation of Nuclear Medicine and Biology Melbourne, April 2018



Digestive Disease Week®

Digestive Disease Week Washington, June 2018

Partnering with leading cancer centres

15 leading cancer centres participating in Global Pancreatic Cancer clinical programme

Region	Centre				
****	MD Anderson, Texas	THE UNIVERSITY OF TEXAS	MOFFI CANCER CEN		
	Johns Hopkins, Maryland	Cancer Center	CANCER CEN		
	Moffit Cancer Centre Florida	COS	JOHNS HOPKINS	HOPKINS	
	Cedars Sinai Hospital, LA	CEDARS-SINAI MEDICAL CENTER.	Ш ме	DICINE	
	Guy's & St Thomas', London	UNIVERSITY OF	Guy's and St Thomas'		
	University of Leicester	UNIVERSITY OF LEICESTER			
	Hammersmith, London	Hammersmith	Addenbroo	enbrooke's NHS	
	Addenbrookes, Cambridge	Hospital	NHS Trust		
	Monash, Melbourne				
	St Vincent's, Sydney	Monash Health	WESTMEAD HOSPITAL	Royal Adelaide	
1 ★ *	Westmead Hospital, Sydney		HOSPITAL	Hospital	
* *	RNS Hospital, Sydney	Austin Health	ST VINCENTS HOSPITAL	Royal North	
	Royal Adelaide		HOSPITAL SYDNEY	Shore Hospital	
	The Austin Hospital, Melbourne				
	Jules Bordet Institute Hospital, Brussels	•{			

JULES BORDET

Clear pathway to commercialisation

Strategic partners provide multiple paths to market to optimise value

Well positioned for commercialisation



Broad technology platform *Treatment for multiple solid tumours*



Excellent clinical results *Pancreatic and primary liver cancer*



EU regulatory approval *CE Mark certification for pancreatic cancer expected near-term*



Significant unmet clinical need

Over130,000 patients diagnosed with pancreatic cancer in US and EU every year

Potential paths to market




2018 marks the start of this journey

1. GLOBOCAN 2012: Estimated Cancer Incidence Worldwide in 2012 (IARC/WHO). Accessed 22 Apr 2016,from http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

Target markets Annual incidence

Globa	l op	porti	unity
-------	------	-------	-------

Pancreatic cancer	US>\$2.0bn	
Liver cancer	US\$1.4bn	




1. GLOBOCAN 2012: Estimated Cancer Incidence Worldwide in 2012 (IARC/WHO). Accessed 22 Apr 2016, from http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

2. Datamonitor Healthcare 2013

3. OncoSil dose pricing, \$USD 25,000

Global Commercial opportunity in excess of \$2bn

130,000 cases per year in US+EU alone: more than 70,000 of these could benefit from OncoSil




More than 70,000 relevant patients in EU and US alone

Company exploring clinical research options in re-sectable & borderline re-sectable patients

OncoSil's potential pricing of US\$25,000 per patient (in-line with other on-market devices) implies >**\$2bn global market** opportunity


OncoSil's commercial path has precedent

Sirtex provides a useful case study to demonstrate the potential commercial journey for OncoSil due to similarities in addressable market



Sector M&A trends

Over A\$2bn of acquisitions in February 2018 highlights attraction of early-stage Australian biotech to global pharmaceutical players



Note:

1. Based on disclosed consideration

2. Based on disclosed premium to target's volume weighted average price prior to announcement

Board of Directors

- Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at **Cochlear** (ASX:COH), **Sirtex Medical** (ASX:SRX), ABIVAX, Baxter International, Roche and more
- Extensive leadership experience guiding products from clinical development to commercialisation
- 120+ years collective experience in the health care industry



Dr Chris Roberts Chairman

- Former CEO/President of Cochlear (ASX:COH)
- 40+ years' industry experience
- Former Chairman of Sirtex (ASX: SRX) & Executive Vice-President of ResMed (ASX: RMD)



Mr Daniel Kenny CEO & MD

- Proven biopharma professional, leading multiple \$1bn+ franchises
- 30+ years industry experience
- Commercial development at ABIVAX & global strategic marketing & business development at Roche



Dr Roger Aston Non Executive Director

- Biotech & pharma entrepreneur
- 20+ years industry experience
- Founder & former CEO of pSiMedica & pSiOncology
- FDA & EU registration, global licensing & equity capital raisings experience



Martin Cross Non Executive Director

- Former Chairman of Medicines Australia
- Highly regarded pharmaceutical executive with 30+ years experience in corporate & industry leadership roles

Highly experienced management team

- Management team experienced leaders in the medical device space having held senior positions at **Sirtex** Medical (ASX:SRX)
- Extensive leadership experience in clinical studies, commercialisation and manufacturing & operations



Mr Daniel Kenny CEO & MD

- Proven biopharma professional, leading multiple \$1bn+ franchises
- 30+ years industry experience
- Commercial development at • ABIVAX & global strategic marketing & business development at Roche



Mr Tom Milicevic Chief Financial Officer & Company Secretary

- Seasoned CFO with over . 15+ years experience in the Medical Device sector
- Experience in investor relations and also Company Secretary duties



Dr Ashish Soman Chief Medical Officer

- Former country medical director, AstraŹeneca Australia.
- 20+ years' experience in clinical practice & the biopharmaceutical industry



Dr David James Manufacturing &

Operations Manager

- Ex Sirtex Medical global • operations manager for 6 years
- Established Sirtex's . manufacturing and operations
- 25 years experience in • pharmaceutical operations



Nicole Wilson VP Regulatory Affairs & Quality


- Regulatory affairs specialist focused on quality compliance and marketing registrations in the Asia, South America and middle Fast.
- Principal for the regulatory approvals in Brazil, Argentina and UAE for Sirtex.



Michael Warrener Global Sales & Marketing Director

- Eormer Sirtex Medical Senior Executive
- Introduced Sir-Spheres in . Australia, EU and Middle East markets

Key catalysts in CY 2018



Strategic partnerships

- Securing strategic partnerships and licensing agreements in key geographies
- Additional Licensing partners in unique geographies

Important notice

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory reguirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect. actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au

OncoSil Medical Ltd www.oncosil.com.au

T: +61 2 9223 3344 **F:** +61 2 9252 3988



OncoSil Medical 21